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I NTRODU CTION
The illness of sch izoph re n ia, as it is understood today, appears to co nsis t of a
heterogeneous group o f di sorders wh ich sha re several common features, suc h as
partial response to medications, poor long-t erm prognosis, and th e presen ce of
psychotic sympto ms . These psychotic symptoms have been arbitraril y d ivided
into two subgroups , positive and negative, in an attempt to better understand
this di sease process (1,2). The positi ve sympto ms, suc h as delusions and hallu ci-
nations, ge nera lly ha ve an acute o nse t with frequent exacerbations and rem is-
sions and a favorable long-t erm prognosis and response to med ica tions. T he
negati ve sympto ms , whic h include affec tive blunting , socia l withdrawal , apa thy,
and an hedonia, tend to be chron ic and typi call y fa il to respond satisfacto ril y to
sta ndard neuroleptics (3) . T his fact has been illustra ted in so me schizophren ic
patients by th e rete ntio n of negat ive symptoms even after trea tm ent and
subsequent re d uc tio n of their posit ive sym ptoms. Researche rs ha ve co ncl uded
th at th e negati ve sympto ms are more refract o ry th an th eir positive counterpa rts
based upon th is freq ue ntly observed phenomeno n (4) .
T h is resista nce has led to a search fo r agents more effective than the
sta nda rd neu roleptics in re lieving the emotiona l wit hdrawa l, social iso latio n, and
apathy of this " deficit" state . Research which uti lizes such medications as
L-d opa , su lpir ide, and a lprazolam for th e treatment of th ese negative sympto ms
is cur rently under way (5). Gould and co -worke rs have found that members of
th e diphen ylbutylpipe ridine group of neuroleptics, suc h as pimozide, seem to be
uniquely suite d fo r th e treatment of negati ve sch izo phrenic symptoms. T hese
neuroleptics are str uc tura lly sim ilar to ve rapa rni l-like d rugs and have strong
ca lcium blocking effects with in th e ce ntra l nervous system (6). It is this unique
effec t upon ca lcium cha nne ls that is thought to be respon sibl e fo r their efficacy
in relieving th e negative symptoms. Lithium car bona te, wh ich a lso sha res
sim ilar it ies to verapamil in th at it alte rs ca lcium metaboli sm , blocks depolariza-
tion , and competes with ca lcium ions within th e neuromuscula r ce lls, has been
useful in treating th e negati ve symptoms of sch izop hrenia as well (7). Verapamil
itsel f has been used successfully as a replacement fo r lith iu m carbonat e in th e
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treatment of acute mania (8 ,9) . It has also been used in preliminary studies to
treat acute exace r bat io ns of schizophrenia (10), but its usefulness in treating th e
negative symptoms ofschizophrenia ha s ye t to be exp lored . We report a case of a
sch izoph renic patient with prominent negative symp to ms, previously resistant to
treatment with the standard neuroleptics, that responded to verapam il.
CASE REPORT
The patient, a 36-year-o ld white male, was fir st seen becau se of his bizarre
behavior and persistent auditory hallucinations. T he patient was livin g in a
group home at the time , and had been refusing to leave his bedroom closet
because th e voices in his head told him to stay in th e closet. O verall , he was
socia lly withdrawn and noncommunicati ve fo r most of th e t ime. He felt anergic
and found it diffi cult to get involved in th e ac t ivit ies at th e group home . His
affect was flat with little variation. He denied feeling depressed and did not
exhibit an y disorder of his sleep or appetite. He first sta rt ed havin g psychiatr ic
problems at th e ag e of 18, wh en he was ho spitali zed fo r psycho t ic be havior.
Sin ce th en he had had four other hospitali zations and had been on various
neuroleptics, as well as short trials of lithium carbonat e , oxazepam, and amitrip-
tylin e. At th e present time, he was receiving thiothixen e 40 mg/ day and
trihex yphenidyl hydrochloride 2 mg twice daily. For th e most part , his hall uci-
nations, delusions, and o ther positive sympto ms responded well to medications,
however, he had a lways been withdrawn , lacked th e motivation to do things, and
showed very little emot io n at all.
Because of his partial response to neuroleptics in th e past , it was decided
that th e patient be included in an ongoing research project th at was in vest igat-
ing th e use of verapamil, a ca lcium channel blocker, to treat th e negative
sympto ms of schizophrenia. The patient was told th at he would rece ive eithe r
vera pa mil, haloperidol , o r pla cebo during the co urse of the study, and could
withdraw at any time and cont inue to recei ve treatment. He signed informed
consent form s at this time.
A complete physical examinat ion as we ll as an electroca rd iogram , an
e lec troencepha logra m, and routine laborato r y tests suc h as co mplete blood
count with differential , serum elec trolytes, g lucose , RPR , and live r and th yroid
fun cti ons were all normal. The patient was ini tiall y sta r te d on haloperidol and
th e dose was gradually increased to 20 mg/day afte r two week s. At th is time he
state d that th e auditory hallucinations had become less bothersome and he no
longer responded to th eir commands. He cont inue d , howeve r , to be sociall y
withdrawn and ane rgic, exh ibiting mark ed anhedonia and blunti ng of affect.
After six week s of treatment with haloperidol , 30 mg/day, he showed no furth er
improvement. Placebo was started at this time, but after fou r wee ks he was on ce
aga in responding to his auditory hallucinations. The placeb o was d iscont inued
and verapam il was star ted at a dose of 80 mg twice da ily. T he verapamil was
grad ua lly increased to 320 mg/day by th e second wee k. Upon eva luation , th e
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patient reported an absence of auditory hallucinations a nd he seemed somewhat
brighter and more talkative. Over the next fou r weeks he was no ted to be more
active on th e unit and he exh ib ite d a great er range of affect. In fact , at on e po int
he was found playing a joke on severa l sta ff members. The patient to lerated the
haloperidol, placebo, and verapamil well , noting o nly some in itial sedation with
the haloperidol and dizziness with the ve rapamil. These side e ffec ts passed
quickly, and weekly vital signs, as well as bi-monthly e lec trocardiograms, were a ll
unremarkable. The patient was dis charged on verapamil80 mg four t imes da ily,
and he has continued to do well for th e last six months.
CO NC LU SIO N
Although this is only a single case report, the ev idence suggests tha t
verapamil can be effective in th e treatment of schizophrenia. More specifica lly,
verapamil seemed to be especi all y useful in reducing this pa t ien t 's nega tive
symp to ms, which in th e past had been resistant to treatme nt wit h th e sta ndard
neuroleptics. Single case reports need to be weighed accordin gly, bu t o ne should
be aware that single case reports in th e pa st, suc h as th ose involving alprazolam
or L-dopa in the treatment of schizop hrenia (11,12), have proven to be the
gateway for further inv estigation and success in th e man agement and improve-
ment of negative schizophrenic sym ptoms. The resu lts of th is case at least
suggest th e need for further research on th e use o f verapa m il and other ca lcium
cha nne l blockers to treat th e negative symptoms of sch izop hren ia .
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